<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The safety and efficacy of reduced-intensity conditioning (RIC) followed by allogeneic stem cell transplantation (SCT) for relapsed <z:hpo ids='HP_0002665'>lymphomas</z:hpo> remains unresolved </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a prospective, multicentered, phase II trial </plain></SENT>
<SENT sid="2" pm="."><plain>A total of 170 relapsed/refractory <z:hpo ids='HP_0002665'>lymphomas</z:hpo> received a RIC regimen followed by SCT from sibling donors </plain></SENT>
<SENT sid="3" pm="."><plain>The primary study end point was non-relapse mortality (NRM) </plain></SENT>
<SENT sid="4" pm="."><plain>Histologies were non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL) (indolent (LG-NHL), n=63; aggressive (HG-NHL), n=61; mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), n=14) and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, n=32) </plain></SENT>
<SENT sid="5" pm="."><plain>Median follow-up was 33 months (range, 12-82) </plain></SENT>
<SENT sid="6" pm="."><plain>The results show that frequencies were as follows: cumulative NRM at 3 years, 14%; <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) 35 and 52%, respectively; 3-year overall survival (OS), 69% for LG-NHL, 69% for HG-NHL, 45% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and 32% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> (P=0.058); and 3-year relapse incidence, 29, 31, 35 and 81%, respectively (P&lt;0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Relapse risk differed significantly at 3 years between follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) (14 versus 46%, P=0.04) </plain></SENT>
<SENT sid="8" pm="."><plain>Molecular remission occurred in 94 and 40% (P=0.002) of patients with FL and CLL, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>On multivariate analysis, OS was influenced by chemorefractory disease (hazard ratio (HR)=3.6), diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> (HR=3.5), and <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (HR=5.9) </plain></SENT>
<SENT sid="10" pm="."><plain>RIC allogeneic SCT is a feasible and effective salvage strategy in both indolent and aggressive NHL </plain></SENT>
</text></document>